76.36
price down icon1.50%   -1.16
after-market Handel nachbörslich: 76.36
loading
Schlusskurs vom Vortag:
$77.52
Offen:
$77.25
24-Stunden-Volumen:
2.49M
Relative Volume:
0.54
Marktkapitalisierung:
$45.81B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$4.18B
KGV:
10.91
EPS:
7
Netto-Cashflow:
$623.10M
1W Leistung:
-2.23%
1M Leistung:
+3.64%
6M Leistung:
+7.70%
1J Leistung:
-13.37%
1-Tages-Spanne:
Value
$75.28
$77.37
1-Wochen-Bereich:
Value
$75.28
$78.46
52-Wochen-Spanne:
Value
$58.93
$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Name
Firmenname
Edwards Lifesciences Corp
Name
Telefon
(949) 250-2500
Name
Adresse
ONE EDWARDS WAY, IRVINE, CA
Name
Mitarbeiter
15,800
Name
Twitter
@edwardslifesci
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
EW's Discussions on Twitter

Vergleichen Sie EW mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
EW
Edwards Lifesciences Corp
76.36 45.81B 5.54B 4.18B 623.10M 7.00
Medical Devices icon
ABT
Abbott Laboratories
133.40 232.39B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
100.04 154.11B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
382.28 145.55B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
87.45 107.35B 33.54B 4.66B 5.19B 3.62

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-24 Hochstufung Piper Sandler Neutral → Overweight
2025-01-30 Hochstufung Stifel Hold → Buy
2025-01-16 Herabstufung Wolfe Research Peer Perform → Underperform
2024-12-16 Hochstufung BofA Securities Neutral → Buy
2024-10-11 Fortgesetzt Morgan Stanley Equal-Weight
2024-09-18 Herabstufung Jefferies Buy → Hold
2024-07-31 Hochstufung Daiwa Securities Neutral → Outperform
2024-07-29 Hochstufung Wolfe Research Underperform → Peer Perform
2024-07-25 Herabstufung BofA Securities Buy → Neutral
2024-07-25 Herabstufung JP Morgan Overweight → Neutral
2024-07-25 Herabstufung Robert W. Baird Outperform → Neutral
2024-07-25 Herabstufung TD Cowen Buy → Hold
2024-07-25 Herabstufung Truist Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-05-22 Hochstufung Citigroup Neutral → Buy
2024-05-14 Hochstufung Deutsche Bank Hold → Buy
2024-03-07 Hochstufung BofA Securities Neutral → Buy
2024-02-02 Hochstufung Wells Fargo Equal Weight → Overweight
2024-01-04 Herabstufung Evercore ISI Outperform → In-line
2023-12-11 Herabstufung Citigroup Buy → Neutral
2023-11-28 Herabstufung Wolfe Research Peer Perform → Underperform
2023-09-26 Hochstufung Oppenheimer Perform → Outperform
2023-07-19 Eingeleitet Robert W. Baird Outperform
2023-05-30 Fortgesetzt Morgan Stanley Overweight
2023-03-29 Eingeleitet UBS Neutral
2023-03-08 Herabstufung Wells Fargo Overweight → Equal Weight
2023-02-06 Herabstufung Raymond James Outperform → Mkt Perform
2023-01-31 Herabstufung Bernstein Outperform → Underperform
2023-01-30 Herabstufung Piper Sandler Overweight → Neutral
2022-12-06 Herabstufung Stifel Buy → Hold
2022-10-28 Herabstufung Oppenheimer Outperform → Perform
2022-10-26 Eingeleitet Mizuho Buy
2022-10-18 Eingeleitet Barclays Overweight
2022-10-12 Eingeleitet Jefferies Buy
2022-07-29 Herabstufung Canaccord Genuity Buy → Hold
2022-04-13 Eingeleitet Truist Buy
2022-04-06 Eingeleitet Wolfe Research Outperform
2022-03-16 Hochstufung Bernstein Mkt Perform → Outperform
2022-03-02 Fortgesetzt BofA Securities Neutral
2022-02-02 Hochstufung UBS Neutral → Buy
2022-01-27 Bestätigt Citigroup Buy
2022-01-27 Bestätigt Evercore ISI Outperform
2022-01-27 Bestätigt Raymond James Outperform
2022-01-27 Bestätigt Stifel Buy
2022-01-27 Bestätigt UBS Neutral
2021-12-17 Hochstufung JP Morgan Neutral → Overweight
2021-12-15 Hochstufung Citigroup Neutral → Buy
2021-12-10 Eingeleitet RBC Capital Mkts Outperform
2021-12-06 Hochstufung Wells Fargo Equal Weight → Overweight
2021-07-30 Bestätigt Canaccord Genuity Buy
2021-07-30 Bestätigt Deutsche Bank Hold
2021-07-30 Bestätigt Jefferies Buy
2021-07-30 Bestätigt Morgan Stanley Overweight
2021-07-30 Bestätigt Oppenheimer Outperform
2021-07-30 Bestätigt Stifel Buy
2021-07-30 Bestätigt UBS Neutral
2021-07-30 Bestätigt Wells Fargo Equal Weight
2021-05-25 Eingeleitet Barclays Overweight
2021-04-15 Eingeleitet Atlantic Equities Neutral
2021-04-05 Hochstufung Evercore ISI In-line → Outperform
2020-12-16 Herabstufung Citigroup Buy → Neutral
2020-12-11 Bestätigt Canaccord Genuity Buy
2020-09-11 Eingeleitet Wolfe Research Underperform
2020-04-28 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-03-05 Eingeleitet Citigroup Buy
2020-02-13 Eingeleitet Goldman Neutral
2020-02-06 Fortgesetzt BTIG Research Neutral
2020-01-10 Eingeleitet Oppenheimer Outperform
2020-01-02 Herabstufung Evercore ISI Outperform → In-line
2019-10-24 Bestätigt Canaccord Genuity Buy
2019-09-23 Eingeleitet Piper Jaffray Overweight
2019-07-24 Bestätigt BofA/Merrill Buy
2019-03-18 Bestätigt Canaccord Genuity Buy
2019-01-18 Hochstufung BofA/Merrill Neutral → Buy
2019-01-03 Eingeleitet Deutsche Bank Hold
2018-11-28 Eingeleitet UBS Neutral
2018-10-16 Eingeleitet Barclays Underweight
2018-10-02 Herabstufung BofA/Merrill Buy → Neutral
2018-10-02 Herabstufung Guggenheim Buy → Neutral
Alle ansehen

Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten

pulisher
Jun 06, 2025

Is Edwards Lifesciences Stock Underperforming the Dow? - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com

Jun 06, 2025
pulisher
Jun 05, 2025

Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan

Jun 05, 2025
pulisher
Jun 02, 2025

DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com

May 30, 2025
pulisher
May 28, 2025

Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Edwards Lifesciences stock rises following competitor’s exit - Investing.com

May 28, 2025
pulisher
May 24, 2025

Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com

May 24, 2025
pulisher
May 23, 2025

Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech

May 23, 2025
pulisher
May 23, 2025

Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance

May 23, 2025
pulisher
May 22, 2025

Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga

May 22, 2025
pulisher
May 22, 2025

Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice

May 22, 2025
pulisher
May 22, 2025

Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com

May 22, 2025
pulisher
May 21, 2025

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com

May 21, 2025
pulisher
May 20, 2025

Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing

May 18, 2025
pulisher
May 16, 2025

Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at StockNews.com - Defense World

May 16, 2025
pulisher
May 15, 2025

Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post

May 15, 2025
pulisher
May 15, 2025

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes - Cardiovascular Business

May 15, 2025
pulisher
May 14, 2025

Edwards Lifesciences Completes Sale of Critical Care - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq

May 14, 2025
pulisher
May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com

May 13, 2025
pulisher
May 12, 2025

FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal

May 12, 2025
pulisher
May 09, 2025

Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance

May 08, 2025
pulisher
May 02, 2025

Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice

May 01, 2025
pulisher
May 01, 2025

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy - Investing.com

May 01, 2025
pulisher
May 01, 2025

Edwards Lifesciences nets FDA approval opening up TAVR to patients before they show symptoms - Fierce Biotech

May 01, 2025
pulisher
Apr 30, 2025

Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey

Apr 30, 2025

Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$85.68
price down icon 1.14%
$71.67
price up icon 0.07%
medical_devices STE
$242.70
price down icon 0.42%
$305.66
price down icon 1.96%
medical_devices PHG
$23.48
price up icon 0.09%
Kapitalisierung:     |  Volumen (24h):